function in chronic renal failure: (1) 
smoking, and diabetes; (2) factors peculiar to chronic tality. Part of their increased risk is due to a higher prevalence renal failure (i.e., anemia and secondary hyperparathy- elsewhere [3] and will not be discussed in this review.
concentric hypertrophy of the left ventricle in these patients.
The high cardiovascular risk of the uremic population Hypertension control, as well as appropriate treatment of anemia and cessation of smoking, constitutes a fundamental area depends, in part, on the fact that these patients represent of intervention in dialysis patients. It appears possible that, in a highly selected population in whom traditional risk facthe near future, control of chronic inflammatory processes of tors are over-represented. However, traditional risk fachigh sympathetic activity and endothelial dysfunction will furtors do not fully explain the high cardiovascular risk ther help to curb the exceedingly high cardiovascular mortality of patients on chronic dialysis treatment. observed in ESRD.
TRADITIONAL RISK FACTORS DO NOT FULLY Cardiovascular morbidity and mortality in patients
EXPLAIN THE HIGH CARDIOVASCULAR with end-stage renal disease (ESRD) is a problem of MORTALITY IN ESRD epidemic dimension [1] . In the United Stated Renal Data
In the general population individual risk can be reliSystem, cardiovascular mortality is five times higher in ably predicted by using cardiovascular risk calculators. very elderly patients (Ͼ85 years) than in coeval controls in the general population. The difference in cardiovascuVarious calculators are freely available on the Internet. lar mortality between the dialysis population and the Some calculators are based on the risk equation of the general population is inversely related to age, and in the Framingham Cohort, others on a equation based on indiyounger cohorts (25 to 35 years), such differences reach vidual data of the major randomized clinical trials, such an astonishing rate of 500 times higher [2] .
as the INDANA project (INdividual Data ANalysis of The main causes of the high cardiovascular mortality in Antihypertensive intervention trials) [4] . If we calculate, ESRD are represented by ischemic heart disease (IHD), using the INDANA calculator, the expected death rate stroke, heart failure, and sudden death (Fig. 1) . Three of a 50-year-old man who smokes, who has had a myocarseries of factors play an important role in vascular damdial infarction, and with a systolic blood pressure of age and in alterations in left ventricular (LV) mass and 140 mm Hg and a serum cholesterol of 190 mg/dL (the average BP and cholesterol in most dialysis centers), the predicted risk of death due to a cardiovascular cause in
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have caused concern among renal physicians because high blood pressure, rather than low blood pressure, identified dialysis patients with longer survival. Yet, these results come as no surprise because the characteristics of patients being studied dictate the expected relationship between arterial pressure and risk. Thus, the relationship is strong and direct in the McMahon metaanalysis that selected patients without cardiovascular complications at baseline, but is U-shaped in several studies in patients with coronary heart disease. Given the high prevalence of cardiovascular comorbidities in the dialysis population, low blood pressure may be a proxy of compromised cardiovascular conditions. The only prospective observational study in dialysis patients that adequately controlled for cardiac function at base- ography) showed that a 10 mm Hg mean blood pressure increase was associated with a 44% higher risk of developing congestive heart failure, and that patients with left ventricular hypertrophy or chronic heart failure are at higher (50%). This difference in risk suggests that in end-stage renal disease traditional risk factors account a much higher risk of mortality than patients without these complications [8] . Heart failure lowers blood presonly partly for the high cardiovascular mortality in these patients.
sure, and the prevalence of heart failure is very high (about 40%) in both incident and prevalent hemodialysis We will discuss traditional risk factors first and then move to uremia-related and emerging risk factors.
patients. Thus, low blood pressure is most often a marker of severe cardiac disease rather than a causal risk factor for cardiovascular mortality in these patients (reverse TRADITIONAL RISK FACTORS causality). Recent analyses in the Cardiovascular Risk Hypertension Extended Evaluation (CREED) cohort have substantially confirmed Foley's study, and indicate that the sysThe role of hypertension in cardiovascular complications in dialysis patients has long been considered an tolic pressure values that minimize cardiovascular risk are in the range between 100 and 150 mm Hg [9] . issue of obvious importance. Such a contention was challenged by studies showing that low, rather than high, Dyslipidemia blood pressure predicts mortality in the dialysis population. In the early 1990s, an extensive meta-analysis Serum cholesterol in ESRD patients is, on average, similar or even lower than that observed in the general of prospective observational studies by MacMahon [5] showed that the risk of cardiovascular events is related population. This phenomenon depends on the fact that malnutrition is pervasive in ESRD. Observational studlinearly to diastolic pressure in the general population, and that such a relationship holds true in the normotenies in dialysis patients have shown that low, rather than high, cholesterol is a marker of high risk in these patients sive range as well. It is important to note that patients included in this meta-analysis had no cardiovascular [10] . These findings have been incorrectly interpreted, indicating that hypercholesterolemia in ESRD should complications before the baseline visit. Of note, the risk reduction associated with lower blood pressure levels in not be a target for intervention. This interpretation is unsound because it ignores the strong evidence accumuthe MacMahon [6] meta-analysis resulted very close to that observed in another meta-analysis dealing with antilated in primary and secondary prevention studies in the general population that indicates a clear benefit of hypertensive drug treatment. In contrast with findings in these meta-analyses, the relationship between blood treating hypercholesterolemia. Thus, when present, hypercholesterolemia should be appropriately treated in pressure and risk is J-or U-shaped in several studies in high-risk populations. In retrospective cohort studies ESRD patients. A controlled clinical trial testing the effect of atorvastatin in diabetic-uremic patients on dialbased on large hemodialysis databases, the risk of mortality is U-shaped. For example, in a study by Zager [7] , ysis is currently underway (the 4D trial). It is important to note that in this study no major side effects have been mortality was higher among patients who were markedly hypertensive or markedly hypotensive after dialysis, and noted in over 500 patients treated for almost three years (C. Wanner, personal communication, 2002). lowest for those with a systolic blood pressure between 150 and 159 mm Hg. This and other subsequent studies Serum Lp(a) is raised in ESRD, and in cross-sectional
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studies it has been associated with coronary heart disease cular complications [19] . These observations are important mostly because a very recent intervention study [11] . To date, no follow-up or longitudinal studies testing the prediction power of Lp(a) for incident cardiovascular reported that controlling hyperphosphatemia and avoiding the administration of calcium carbonate reduces the complications are available. Similarly, there is still no evidence that a selective pharmacologic intervention on progression rate of vascular calcifications in the aorta and in coronary arteries, as well [20] . Lp(a) reduces the risk of cardiovascular disease. Given the high atherogenic potential of this lipoprotein, such studies are worth pursuing.
EMERGING RISK FACTORS Homocysteine Smoking
Smoking is a risk factor of paramount importance. Homocysteine is a sulfur amino acid whose metabolism depends on vitamin B 12 and folic acid. The plasma Recently, it has been implicated in the progression of renal disease in patients with severe hypertension [12] . In levels of homocysteine are markedly raised in dialysis patients, and high homocysteine levels have been associthe Cardiovascular Risk Extended Evaluation in Dialysis (CREED) study, as many as 118 out of 285 (41%) paated with high cardiovascular morbidity in two cohort studies [21, 22] . High-dose folate (5 to 15 mg/day) retients were active smokers. In a detailed echo-color Doppler study of the carotid arteries in this cohort, smokduces the serum concentration of homocysteine, but there are no prospective studies showing that lowering ing was a predictor of the number of atherosclerotic plaques, independent of other risk factors [13] .
serum homocysteine reduces cardiovascular morbidity and mortality.
UREMIA-RELATED CARDIOVASCULAR C reactive protein RISK FACTORS
Inflammation as measured by CRP is considered a Anemia process of primary importance in the pathogenesis of atherosclerosis and of major cardiovascular complicaAnemia has a negative impact not only on quality of life but also on survival. Patients with severe anemia (Ht tions in the general population [23] . In dialysis patients, CRP is a strong predictor of death and cardiovascular Ͻ27%) have a risk of death 60% higher than patients with moderate anemia (Ht 31% to 33%) [14] . Severe anecomplications [24] . Although CRP is also directly involved in cardiovascular damage, its strong prediction mia is an important trigger of LVH because intervention studies have demonstrated that correction of anemia inpower for adverse cardiovascular events depends on it being a risk marker, rather than a causative risk factor. duces a partial regression of LVH independent of arterial pressure [15] . The potential role of anemia on cardiovasFactors responsible for high CRP in patients with ESRD are not completely understood. High CRP has been recular risk is further emphasized by recent observations in patients with heart failure and with modest degrees lated to increased serum levels of anti-Chlamydia antibodies [25], but it is still uncertain if Chlamydia infection of renal insufficiency [16] . On the other hand, the Normal Hematocrit Trial [17] has shown that in patients at high contributes to atherosclerosis in dialysis patients. Dialysate contamination has been proposed as a likely factor, cardiovascular risk, pursuing the ambitious goal of a normal hematocrit (42%) may increase, rather than debut serum CRP increases in the early phases of chronic renal failure, well before starting chronic dialysis treatcrease, mortality. Although the interpretation of this study is debatable, we should not aim at raising the ment. Inflammation is a modifiable risk factor. Aspirin induced a marked decrease in the incidence rate of corohematocrit beyond the currently recommended target (33% to 36%) in dialysis patients at high cardiovascular nary events in the large cohort of apparently healthy subjects enrolled in the Physician's Health Study [26] , risk. Whether a normal hematocrit affords cardiovascular protection in patients at low risk remains to be estaband lovastatin (a drug which lowers cholesterol and possesses anti-inflammatory properties) prevents cardiovaslished.
cular events in patients with high CRP independent of Hyperphosphatemia and hyperparathyroidism its effect on serum cholesterol [27] . Several mechanistic studies indicate that hyperparathyroidism, hypercalcemia, and hyperphosphatemia can OTHER EMERGING RISK FACTORS trigger and/or amplify cardiovascular damage in dialyAsymmetric dimethyl arginine (ADMA) and sis patients. Observational studies demonstrated that cardiovascular damage in ESRD marked hyperphosphatemia (Ͼ7.8 mg/dL) is associated with increased mortality [18] . More recently, it has been NO production is reduced in patients with moderate to severe renal failure, a phenomenon that is mainly shown that a relatively less pronounced degree of hyperphosphatemia (Ͼ6.5 mg/dL) predicts incident cardiovasattributed to the accumulation of the endogenous inhibi-
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tor of NO synthase, ADMA [28] . On the other hand, it ity generates myocardial hypertrophy by mechanisms only partly dependent on raised arterial pressure. In line is well demonstrated that endothelial dysfunction is a pervasive phenomenon in patients with chronic renal with observations suggesting that hypertension only in part accounts for raised LV mass, we have recently rediseases. This phenomenon may influence later morbidity and mortality from large vessel atherosclerotic disease ported that the link between the muscular component of LV mass (mean wall thickness) and plasma NE is and LVH.
It has been argued that it is unlikely that ADMA exerts largely independent of arterial pressure and other risk factors [39] . Furthermore, we have also provided evidence meaningful biologic effects at the plasma concentration measured in vivo in humans [29] . Although there is no that high plasma norepinephrine in dialysis patients is an important trigger for cardiovascular events [40] . conclusive proof that ADMA interferes with the cardiovascular system in uremic man in vivo, most hemody-
The cause of sympathetic overactivity in renal failure is still poorly defined. An alteration in afferent neural namic studies performed so far are compatible with the hypothesis that NO synthase inhibition is implicated in inputs in diseased kidneys is a possible culprit because sympathetic nerve activity decreases in uremic man after the endothelial dysfunction of dialysis patients. Furthermore, cross-sectional [30] and prospective studies bilateral nephrectomy [37] . Nocturnal hypoxemia triggered by sleep apnea seems to be another likely cause. [31] have shown that plasma ADMA concentration is strongly associated to atherosclerotic complications and Sleep apnea is very frequent in ESRD (about 30%), and nocturnal hypoxemia has been associated with a predicts incident cardiovascular events in these patients. Extensive atherosclerosis and LVH represent the main nocturnal increase in arterial pressure [41] , concentric hypertrophy [42] , and adverse cardiovascular outcomes components of the high risk of uremic patients. Therefore, the fact that ADMA is an independent, high-rankin dialysis patients [43] . Nocturnal hypoxemia triggers a marked increase in sympathetic activity that outlasts ing correlate of carotid atherosclerosis [32] and LV concentric hypertrophy [33] also suggests that this substance hypoxemic episodes. Thus, it appears possible that the high sympathetic tone in ESRD at least in part depends is an important factor, mediating a process which may result in important clinical sequels ranging from heart on the high frequency of sleep apnea and nocturnal hypoxemia in this population. Whatever the explanation for failure to coronary and cerebrovascular complications.
high sympathetic tone in patients with chronic renal failSympathetic overactivity and sleep apnea ure may be, this factor is clinically important because it can be modified by using anti-adrenergic drugs. It has Plasma norepinephrine (NE) in ESRD patients was found to be high in most studies performed between the been shown that carvedilol reduces left ventricular volume and improves systolic function in dialysis patients 1970s and the 1980s [34] [35] [36] , and on the basis of these studies, chronic renal failure was considered a situation with ventricular dilatation [44] . Since carvedilol has antioxidant properties, it is difficult to establish whether the characterized by enhanced sympathetic activity. The interpretation of plasma NE as a marker of sympathetic favorable effects of this drug depend solely on its antiadrenergic activity. Yet, this study pragmatically shows activity is complex in patients with renal failure because circulating NE represents only a small proportion of that interfering with adrenergic activity may represent an important intervention area. the neurotransmitter amount secreted from adrenergic nerve terminals, and because these patients display metaReducing cardiovascular risk in dialysis patients is an absolute priority. At this stage we have "evidence-based" bolic alterations which may alter the plasma concentration of this substance. The undisputed standard for the options for intervention for some traditional risk factors only. While it is almost undisputable that hypertension assessment of sympathetic activity is microneurography. This technique has convincingly demonstrated that symis a risk factor to be appropriately treated in dialysis patients, and that those patients should stop smoking, pathetic activity in dialysis patients is increased [37] , and that this increase is even more consistent than it emerged we still don't know whether normalizing hemoglobin in patients without advanced cardiovascular disease may from early studies based on plasma NE measurements.
Left ventricular hypertrophy is an adaptive process help to prevent cardiovascular damage. Furthermore, there are still no intervention studies aimed at modifying aimed at minimizing ventricular wall stress. Several factors, including hypertension and altered circadian arterial serum phosphate based on hard end points, or convincing proof that reducing plasma homocysteine reduces carpressure profile, may influence this process in patients with renal diseases. The evidence that the sympathetic diovascular risk in dialysis patients. Until now, there has been no study proving that interfering with sympathetic system is involved in the progression of cardiovascular structural alterations such as left ventricular hypertrophy activity or with ADMA may reduce the cardiovascular burden of ESRD. Presently, we should pay more attenand arterial remodeling in the general population is now substantial [38] . Norepinephrine promotes myocardial cell tion at systematically using available cardiovascular treatments (e.g., anti-hypertensive drugs, aspirin, and hypertrophy in vitro; in vivo, sustained sympathetic activ-
